Illumina provides sequencing and array solutions to advance genomic research. Their products include instruments, kits, reagents, software, and analysis services.

Illumina

BaseSpace Informatics Suite

Illumina For Startups

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Oxford Nanopore Technologies

SomaLogic

Twist Bioscience

GenoLogics

Ginkgo Bioworks

Grail

Helixis

Bank of America

Lombard Odier

Chase Capital Partners

Chevron Technology Ventures

ARCH Venture Partners

State Farm

Tredegar Investments

Venrock

CW Group

The "chewing gum," made from birch bark pitch and saliva, likely served as glue for tools. Researchers analyzed the #DNA in the gum, revealing the Stone Age teenagers' diet, including deer, trout, apple, duck, fox, and hazelnuts.

May the Year of the Dragon bring you joy, prosperity, and good luck! 🐲 

In 2023, we launched a novel technology to help reach the darkest corners of the genome and make long-read sequencing accessible. Now, we have built upon Illumina Complete Long Read technology with a new highly accurate, targeted long-read solution—compatible with predesigned and fully custom panels—offering greater flexibility for long-read sequencing.
 
Why? To help scientists access more of the genome and find answers to improve human health.

Learn more about Illumina Complete Long Read Prep with Enrichment:
https://bit.ly/3Oliav7


Good things come in threes, and the lineup of #NovaSeqX flow cells are no different. The addition of the 1.5B flow cell to the reagent kit portfolio provides unmatched flexibility to take on smaller batch or pilot projects. 

Scale up your way with the NovaSeq X Series: https://bit.ly/3u8LlKS

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

DNSSEC

Content Delivery Network

Font Awesome

Sue Siegel

William Rastetter

David L. Barker

Daniel M. Bradbury

Roy Whitfield

Philip Schiller

Paul Schimmel

Jay Flatley

Tim Goldsmith

Human Factors Engineer & User-Experience Designer

Simon Valentine

Global Head of Sales, Enterprise Informatics

Greg Apker

Director of Global Commercial Analytics and Data Science

Doohyun Park

Senior Sales Specialist

Steven Barnard

Chief Technology Officer

Jeff Rucker

Principal Engineer 1

Joydeep Goswami

Chief Strategy & Corporate Development Officer

Carissa Rollins

Chief Information Officer

Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology.

Grail is a healthcare company that develops pan-cancer screening tests designed to detect cancers at an early stage.

Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets.

SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.

Twist Bioscience is a biotechnology company that offers synthetic DNA solutions, gene synthesis, and variant libraries.

Desktop Genetics is a biotechnology company to helps researchers discover and treat the root genetic causes of human disease.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

GenoLogics provides biomedical solutions and data management software, advancing the early detection, prevention, and treatment of diseases.

San Diego Companies that Exited

Investors Active in Oxfordshire

Accelerators with Investments in Northeastern US

Western US Companies With More Than $1M in Revenue (Top 10K)

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Post-IPO Debt - Illumina

Venture Round - Illumina

San Diego

California

United States

North America

Trailblazing Study Shows Early CGP Leads to Better Precision Treatments

United States Non-Invasive Prenatal Testing Market Report 2025-2033: Illumina, Roche, and Natera, which have Established Themselves as Leaders through Robust Research and Development

Illumina previews updated tumor research assay, begins shipping IVD kits

Global Biotechnology Reagents & Kits Market Size to Reach USD 1441.03 Billion by 2032 with a CAGR of 11.04% - Research by SNS Insider

Global Life Science and Chemical Instruments Market Set to Reach USD 79.7 Billion by 2034, Projected to Grow at 5.3% CAGR | Future Market Insights, Inc.

Pharmacogenomics Market to Hit USD 8.11 Billion by 2032, at a CAGR 10.3% | VMR

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Spatial Genomics and Transcriptomics Research Analysis Report 2024-2030: Emergence of High-Throughput Sequencing Platforms Fuels Market Growth

DNA Sequencing Research Report 2024 - Global Forecast to 2031: $21.3 Billion Market to Benefit from Growing Use in Clinical Applications and Extensive Genomic Projects - ResearchAndMarkets.com

Thailand

Asia

Japan

India

South Korea

HTML5

Modernizr

Bootstrap

Lead generation and appointment setting

jQuery

Google Fonts

Office 365

Amazon EC2

Microsoft Outlook

Fonts.com

Illumina owns Illumina Ventures

Illumina owns Illumina Accelerator

PacBio is a biotechnology company that develops and manufactures DNA sequencing systems.

PacBio

Oxford Nanopore is a biotechnology company specializing in nanopore-based electronic molecular analysis systems.

Oxford Nanopore

Thermo Fisher Scientific is a multinational biotechnology product development company.

Thermo Fisher Scientific

Affymetrix is a biotechnology company that provides products for genetic analysis.

Affymetrix

Biostars is a platform for bioinformatics and computational biology.

Biostars

Complete Genomics is a biotechnology company specializing in human genome sequencing and analysis.

Complete Genomics

Caliper Life Sciences is a company that develops and markets microfluidic lab-on-a-chip technologies.

Caliper Life Sciences

Sequentify is a biotechnology company that offers sequencing and bioinformatics solutions.

Sequentify

Algorithmic Biologics is a company specializing in computational biology and bioinformatics.

Algorithmic Biologics

P4 Medical Laboratory is a medical diagnostics laboratory offering genetic testing services.

P4 Medical Laboratory

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company's portfolio encompasses sequencing kits and reagents, sequencing tools and systems, microarray kits and reagents, molecular biology reagents, and arrays and reagents. Illumina serves pharmaceutical companies, academic institutions, genomic research centers, biotechnology companies, and clinical research organizations.

news impact assignment basic	general	Feb 15, 2024 6:15 PM	baa0d2c0
public peers	general	Oct 2, 2024 2:39 PM	a529aee8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 2, 2024 2:39 PM	e27e11ca
crunchbase trigger	general	Nov 25, 2024 9:06 AM	88621fa3
crunchbase profile	general	Nov 25, 2024 11:35 AM	d84a94a5
li profile	general	Feb 15, 2024 6:15 PM	b712155a
translate crunchbase fundingrounds	general	Nov 25, 2024 2:14 PM	0738c8d1
peers	general	Oct 2, 2024 2:39 PM	180b7e50
news basic	general	Oct 2, 2024 2:39 PM	1171167c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ILLUMINA

Illumina